Market Intelligence, Clinical Progress, and High-Purity Reagents for Eosinophilic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-5 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-5 Recombinant Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View IL-5 Products |
| Receptor | IL-5Rα (CD125) ECD-Fc Fusion Protein For binding affinity and specificity screening. Theoretical MW verified. |
View IL5RA Products |
| Benchmark Ab | Anti-IL-5 (Sequence of Mepolizumab) Recombinant positive control. Sequence Verified. |
View IL-5 Products |
| Competitor Standard | Anti-IL-5 (Sequence of Reslizumab) Comparator antibody for assay calibration. |
View IL-5 Products |
| Gene Delivery | IL-5 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. |
View IL-5 Products |
| Validator | IL-5 siRNA Set For knockdown verification and specificity controls. |
View IL-5 Products |
| Pathway Partner | IL-5Rα (Beta Common Complex) Critical for heterodimeric receptor signaling assays. |
View IL5RA Products |
| Related Target | IL-4 Synergistic Th2 pathway cytokine; combination therapy target. |
View IL-4 Products |
| Related Target | IL-13 Shared effector pathway in eosinophilic inflammation. |
View IL-13 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval | Human/Mouse/Cyno IL-5 ortholog proteins available with >95% purity; sequence identity verified by mass spec |
| Cytokine selectivity (IL-3/GM-CSF) | IL-5 specific with no cross-reactivity to IL-3 or GM-CSF; Homolog panel proteins strictly verified |
| Receptor heterodimer binding | IL-5Rα/βc co-expression cell lines available; Lentivirus for stable transduction |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization |
| False Positives | Validated siRNA included for specificity checks in cellular assays |
Live IL-5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for IL-5-targeted interventions has matured significantly, with three approved biologics establishing the efficacy of eosinophil depletion in Type 2 inflammation. The race is now shifting toward next-generation modalities including oral small molecule inhibitors of the IL-5/IL-5R interaction, bispecific antibodies targeting IL-5/IL-4 pathways, and biosimilar competition as original molecules face patent cliffs. As first-generation therapies saturate the severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA) markets, the next wave of R&D targets chronic rhinosinusitis with nasal polyps (CRSwNP) expansion, pediatric indications, and severe atopic dermatitis with eosinophilic signatures.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Anti-IL-5 mAb | GSK (Mepolizumab), Teva (Reslizumab) | Severe Eosinophilic Asthma, EGPA, HES | Neutralization Assay (Need high-purity IL-5 and IL-5Rα proteins) |
| Anti-IL-5Rα mAb | AstraZeneca (Benralizumab) | Severe Asthma, COPD | ADCC Functional Assay (Need IL-5Rα overexpressing cell lines) |
| Bispecific | Early Phase Biotechs | Severe Type 2 Inflammation | Heterodimer Validation (Need Cross-reactive Abs and dual-target proteins) |
| Small Molecule | Preclinical/Discovery | Mild-Moderate Asthma (Oral) | Competitive Binding Assay (Need purified IL-5/IL-5Rα ECD) |